These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 15828902)

  • 1. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines.
    Izumi M; Shirai K; Ito K; Miyamoto T; Matsumoto A; Takenaka Y; Nakagawa K; Yamanashi T; Takamitsu Y; Nakanish T
    Ther Apher Dial; 2005 Feb; 9(1):24-31. PubMed ID: 15828902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites.
    Ando R; Naito S; Inagaki Y; Hata T; Ishida Y; Chida Y; Takayama M; Tachibana K; Ohtsuka M; Inoue A
    Ther Apher Dial; 2005 Feb; 9(1):16-23. PubMed ID: 15828901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK; Devlin L; Taal MW; Fluck RJ; McIntyre CW
    Nephrol Dial Transplant; 2005 Aug; 20(8):1643-6. PubMed ID: 15870223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
    Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
    Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
    Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
    Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
    Ogata H; Koiwa F; Shishido K; Kinugasa E
    Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
    Hwang JC; Chen CA; Wang CT; Chen HC
    Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
    Sonikian MA; Pani IT; Iliopoulos AN; Koutala KG; Marioli SI; Vlassopoulos DA
    Ren Fail; 2005; 27(2):143-7. PubMed ID: 15807177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
    Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J
    Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
    Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
    Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.
    Molina Vila P; Sánchez Pérez P; Garrigós Almerich E; Peris Domingo A
    Hemodial Int; 2008 Jan; 12(1):73-9. PubMed ID: 18271845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of reduced dialysate calcium on mineral metabolism in hemodialysis patients].
    Fujimori A; Yorifuji M; Sakai M; Fukagawa M
    Clin Calcium; 2005 Sep; 15 Suppl 1():121-4; discussion 124. PubMed ID: 16272643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.